The U.S. Food and Drug Administration questioned the effectiveness of a new cancer drug being developed by North Jersey-based Genta Inc. in a report released Friday, according to the Philadelphia Business Journal.
FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
New TMB-001 Sub-Analysis Data Published in Clinical and Experimental Dermatology
The Cutaneous Connection: JAK Inhibitor Safety for Treating AD
AAD 2023 Pearls from Zoe Diana Draelos, MD
New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients
2 Clarke Drive Cranbury, NJ 08512